ArticleMedical science monitor : international medical journal of experimental and clinical research2025
Predictive Value of Platelet Aggregation Tests in Recurrent Cerebral Ischemia and Major Bleeding.
Article in Medical science monitor : international medical journal of experimental and clinical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND Evaluating the efficacy of antiplatelet therapy is rarely performed in patients with cerebral ischemia, despite the underlying potential recurrence of ischemia and unexpected bleeding. This study aimed to evaluate the role of platelet aggregation tests, which can predict ischemic recurrence and major bleeding. MATERIAL AND METHODS We measured the platelet aggregation activity of 768 patients using a standardized turbidimetric technique. Ischemia recurred in 8 of 48 patients who received aspirin alone, and recurred in 68 of 142 patients administered more than 1 antiplatelet agent. Major bleeding occurred in 11 of the same 142 patients. Platelet aggregation was induced by the addition of 4.0 and 20 µmol/L of adenosine diphosphate (ADP). The correlations of the maximal aggregation (MaxAgg), disaggregation rate, and aggregation curve area with the recurrence of ischemia and major bleeding were analyzed. RESULTS The MaxAgg in patients without recurrence decreased significantly (74.9%±13.2 to 54.0%±11.3, P<0.001 for 4.0 µmol/L) compared with the values before aspirin treatment. The odds ratio for recurrence (n=68) of total ischemia to non-recurrence (n=74) was 1.057 (1.029-1.086, P<0.001) for 4.0 µmol/L stimulation. The odds ratio for patients with bleeding (n=11) to total ischemia cases (n=142) was 0.828 (0.742-0.924, P=0.001) with 4.0 µmol/L stimulation. CONCLUSIONS The recurrence of ischemia was correlated with the lack of decrease in MaxAgg. Major bleeding was correlated with an excessive decrease in MaxAgg.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.